Ekso Bionics (NASDAQ:EKSO) Issues Earnings Results

Ekso Bionics (NASDAQ:EKSO) posted its earnings results on Monday. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02), Yahoo Finance reports. Ekso Bionics had a negative return on equity of 88.93% and a negative net margin of 68.41%. The company had revenue of $4.95 million during the quarter, compared to the consensus estimate of $5.34 million. During the same period last year, the firm posted ($0.31) EPS.

Ekso Bionics Stock Down 28.6 %

Shares of EKSO stock opened at $1.06 on Wednesday. The stock has a market cap of $19.26 million, a P/E ratio of -1.09 and a beta of 1.51. Ekso Bionics has a 52 week low of $0.62 and a 52 week high of $3.13. The company has a quick ratio of 2.11, a current ratio of 2.81 and a debt-to-equity ratio of 0.33. The company’s fifty day simple moving average is $1.15 and its two-hundred day simple moving average is $1.47.

Analysts Set New Price Targets

EKSO has been the subject of a number of research analyst reports. Lake Street Capital started coverage on shares of Ekso Bionics in a research report on Monday, June 24th. They issued a “buy” rating and a $2.50 target price for the company. StockNews.com started coverage on shares of Ekso Bionics in a research report on Tuesday. They set a “hold” rating for the company. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Ekso Bionics in a research report on Tuesday.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.